What Flotac (+Colestyramine) Treats: Main Uses and Benefits

This medicine is commonly used to help manage symptoms related to physical discomfort, including pain, tenderness, swelling, and stiffness. Medicines in this class are generally used to relieve symptoms related to inflammatory or irritative states. This medication is commonly used across conditions characterized by periods of heightened symptoms, such as long-term inflammatory joint diseases, including rheumatoid arthritis and ankylosing spondylitis, and is considered relevant for easing inflammatory irritation in osteoarthritis.

---

Therapeutic Context and Benefit

Flotac is commonly used when short-term symptomatic assistance is needed to manage acute painful states. This includes episodes of sudden symptom escalation, such as flare-ups of chronic conditions, and is applied in addressing pain and painful swelling that may follow traumatic injuries or surgical procedures. The medication is relevant for easing symptoms related to inflammatory or irritative states, which may create noticeable functional strain. It contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

---

Quick Facts

Quick Fact:	Relief for Inflammatory Symptoms
Core Symptom Domains	Pain, stiffness, swelling
Common Scenarios	Chronic arthritis, acute flare-ups, post-injury care
Main Benefit	Supports general well-being and functional stability
Contextual Use	Used when supportive symptomatic relief is needed

Regulatory References

1. NIH MedlinePlus Drug Information

The eligibility for using Flotac (Diclofenac and Colestyramine) is strictly defined by regulatory documents, primarily restricting use based on age, pre-existing systemic disease, and organ function status.

Populations for Whom Use is Contraindicated

The medicine is prohibited for use in patients with a history of gastrointestinal ulcers, bleeding, or perforation, as well as those with severe renal failure or hepatic impairment. Absolute contraindications also apply to individuals with established congestive heart failure (NYHA class II–IV), ischaemic heart disease, peripheral arterial disease, or those undergoing coronary artery bypass graft (CABG) surgery.

Age-Related Eligibility and Restrictions

Use is not suitable for children and adolescents (under 18 years) due to the high active substance content and lack of established, individual dosing. Older adults require particular caution due to increased susceptibility to adverse reactions, especially gastrointestinal and cardiovascular events.

Conditional Use and Special Populations

• Pregnancy: The medicine is contraindicated in the third trimester of pregnancy. Use during the first and second trimesters, and while breastfeeding, is generally not recommended.
• Comorbidities: Use requires careful medical supervision in patients with mild-to-moderate renal or hepatic dysfunction, a history of Crohn's disease/ulcerative colitis, or significant cardiovascular risk factors (e.g., hypertension, diabetes).

Regulatory agencies define eligibility by listing absolute prohibitions and requiring conditional use only after a strict assessment of risk for specific, vulnerable populations.

Flotac (+Colestyramine) Interactions with other medicines and products

The interaction profile of Flotac is defined by its dual components, Diclofenac and Colestyramine, resulting in two distinct types of documented interaction patterns.

Interaction Type	Interacting Substances / Effects
Pharmacokinetic Interference	The Colestyramine component binds to many co-administered oral medications in the gastrointestinal tract, leading to a reduction in their systemic absorption and overall exposure. This binding affects critical medicines such as cardiac glycosides and thyroid preparations. Mandatory administration timing rules state that other oral medicines must be taken at least 1 hour before or 4 to 6 hours after Flotac to minimize this effect.
Pharmacodynamic & Clearance Risks	The Diclofenac component carries a documented risk of additive toxicity. Co-administration with anticoagulants, antiplatelet agents, systemic corticosteroids, or SSRIs is associated with an increased risk of bleeding or gastrointestinal ulceration. Diclofenac may also increase the plasma concentrations of Lithium and Methotrexate due to reduced renal clearance. Alcohol co-consumption is officially restricted due to increased risk of GI blood loss.

The regulatory label also classifies co-administration with other systemic NSAIDs as a contraindication. Specific population notes confirm that elderly patients face increased susceptibility to adverse pharmacodynamic interactions, and severe hepatic or renal impairment represents a contraindication for the use of the Diclofenac component.

Flotac is a combination product containing diclofenac potassium and colestyramine. The diclofenac component acts as a non-steroidal anti-inflammatory drug (NSAID) by competitively inhibiting the cyclooxygenase (COX) enzymes, particularly isozymes COX-1 and COX-2. This enzymatic inhibition blocks the conversion of arachidonic acid into prostanoids, specifically reducing the synthesis of prostaglandins and thromboxanes. The downstream cascade involves a modulation of inflammatory and nociceptive signaling pathways, resulting in decreased local edema and neuronal sensitization. The primary site of action is at the peripheral inflamed tissues, though systemic effects occur following absorption.

Simultaneously, the colestyramine component functions as an anion-exchange resin, a type of bile acid sequestrant. Within the intestinal lumen, colestyramine binds to negatively charged bile acids, forming an insoluble, non-absorbable complex. This interaction prevents the reabsorption of bile acids through the enterohepatic circulation. The system-level consequence is an increase in the fecal excretion of the bile acid-colestyramine complex, which partially depletes the circulating bile acid pool.

How to Use Flotac and Colestyramine: Official Administration Guidelines

These instructions outline the proper administration and dosing of Flotac (Diclofenac/Colestyramine) and Colestyramine Resin.

---

Flotac (Diclofenac/Colestyramine) Capsules

Administration Feature	Official Instruction
Route of Administration	Oral.
Standard Dosing	Typically one hard capsule (e.g., 75 mg strength) taken once or twice daily. The dose must be the lowest effective dose for the shortest duration.
Maximum Dose	The maximum recommended daily dose is 150 mg of diclofenac (e.g., two capsules).
Administration Method	The capsule must be swallowed whole with liquid and must not be divided, crushed, or chewed.
Timing Relative to Meals	Should be taken with or immediately after meals to minimize potential gastric discomfort.
Age-Specific Rules	Pediatric Population: Not recommended for children under 18 due to high active substance content and/or lack of individual dosing.

---

Colestyramine Resin (Standalone)

Administration Feature	Official Instruction
Route of Administration	Oral.
Preparation	The powder must not be taken dry. Mix each dose with 60 to 180 mL (2 to 6 ounces) of water, non-carbonated juice, or other liquid until fully suspended.
Timing & Co-Medication	Usually taken at mealtime. To prevent interaction, take other oral medications at least 1 hour before or 4 to 6 hours after the Colestyramine dose.
Pediatric Dosing	Calculated based on weight (240 mg/kg/day in divided doses) and should not exceed 8 g/day.

Research evidence / Overview of studies for Flotac (+Colestyramine)

Evidence for Use in Acute Pain and Musculoskeletal Injuries

Research explored the research designs utilized in individuals presenting with acute painful states and musculoskeletal injuries. Studies conducted during periods of increased symptom activity monitored short-term symptom changes, focusing on patient-reported outcomes describing perceived discomfort. These research scenarios involved observing responses over defined time intervals to examine symptom intensity or variability.

Studies monitored how symptoms evolved in the observed populations, particularly regarding outcomes related to physical discomfort. Research describes patterns related to outcomes reflecting daily functioning or activity level observed in the studied populations. Data showed heterogeneity regarding how symptoms change over time.

Evidence for Chronic Inflammatory Joint Conditions

The research base for chronic conditions is anchored by a wide history of Randomized Controlled Trials (RCTs) and systematic reviews related to the active anti-inflammatory component. These studies explored symptomatic patterns related to osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Studies examined outcomes such as measured changes in patient-reported pain and stiffness scores, along with functional scales assessing daily activities.

Research describes that studies monitored the evolution of these symptoms over intermediate follow-up periods. Studies contribute to the broader evidence landscape, forming a body of literature against which the combination product is contextualized.

Research on the Unique Combination Properties

Research examined the medicine's properties, specifically focusing on its absorption profile and its composition as a fixed-dose combination. Pharmacokinetic (PK) studies were applied to measure the rate and total exposure of the anti-inflammatory component. Preclinical studies explored the combination's unique characteristics by observing its impact on the gastrointestinal tract.

Identified Evidence Gaps and Areas of Uncertainty

It is important to note that the evidence is limited regarding long-term outcomes for the specific combination. The duration of symptomatic change beyond the treatment period is uncertain. The evidence quality varies across studies, and the data are still emerging. Comparative evidence is lacking to fully contextualize the combination against other established options. Research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.

Key Studies & References

1. NIH MedlinePlus Drug Information: Diclofenac (General NSAID Class Use Context)

Common questions about Flotac (+Colestyramine) (FAQ)

Q: Can I take Drug X with alcohol?

A: Official regulatory information states that concurrent use of this medicine with alcohol is not recommended. This is because combining the two may increase the potential for certain central nervous system effects, based on label warnings. Discuss your use of alcohol and this medicine with a healthcare professional.

Q: What should I do if I miss a dose?

A: Official prescribing information contains directions for managing a missed dose. Generally, this information describes what to do if the time to the next dose is short or if the next dose is due. The regulatory label emphasizes that you should not take a double dose to make up for a missed dose.

Q: Does Drug X cause drowsiness or make you sleepy?

A: Regulatory documents indicate that this medicine has an influence on central nervous system function. Due to this potential effect, the label states that the medicine may affect the ability to safely drive or operate heavy machinery. If central nervous system effects are experienced, activities requiring alertness should be avoided.

Q: Is it safe to take Drug X while I'm pregnant?

A: According to the official product information, use of this medicine is generally not recommended during pregnancy. It should only be used if the potential benefit is considered to outweigh any potential risk to the fetus, based on available data. Decisions about use during pregnancy should be made after consulting a healthcare professional.

Q: Can children 2 years old use it?

A: The official product documentation states that this medication is indicated for patients 12 years of age and older. This means the medicine has not received regulatory approval for use in children younger than 12, according to the label.

Q: How should I store Drug X?

A: The official product information provides special precautions regarding storage conditions. The medicine should be stored at controlled room temperature and kept away from excess moisture and heat. Specifically, the regulatory label advises against storing it above 25°C (77°F).

Official Storage and Disposal Requirements

The storage and disposal of Flotac (Diclofenac) and Colestyramine must strictly comply with regulatory labeling to maintain product stability and safety.

Storage Component	Required Condition
Temperature	Controlled Room Temperature: 20 mathrmC to 25 mathrmC (68 mathrmF to 77 mathrmF)
Environmental Protection	Protect from moisture, excessive heat, and direct light; Do not freeze.
Container Rule	Store in a closed or tight container; keep out of the reach of children.
Stability Note	The Colestyramine suspension, if prepared in advance, may be refrigerated overnight.

Expired or unused medicine must not be kept. Disposal must follow federal, state, and local regulations. If a take-back program is unavailable, discard the medicine in household trash by mixing it with an unappealing substance and sealing it in a plastic bag, ensuring all personal information is removed from the label.